Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 1.00 |
| ▸ | DUOX2 | Q9NRD8 | 1/20 | 1.00 |
| ▸ | DUOX1 | Q9NRD9 | 1/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027831 | 1.00 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4923550 | 0.89 | CYBB (0.80) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4920436 | 0.88 | CYBB (0.78) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4928536 | 0.84 | CYBB (0.73) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4920666 | 0.83 | CYBB (0.71) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL15313075 | 0.83 | CYBB (0.69) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4920220 | 0.81 | CYBB (0.69) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4928611 | 0.81 | CYBB (0.68) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL17210872 | 0.80 | CYBB (0.67) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL29490371 | 0.79 | CYBB (0.66) | CYBBNOX5NOX4DUOX2DUOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| EP-4205750-B1 | NADPH OXIDASE INHIBITOR FOR SUPPRESSING OR IMPROVING HAIR LOSS OR TREATING ALOPECIA | EADERM CO LTD (JP) | 2025-04-09 | — | — | EP | claimed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| CN-118079006-A | Skin composition | 国立大学法人东京医科齿科大学 | 2024-05-28 | — | — | CN | claimed |
| US-20240066021-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-29 | — | — | US | claimed |
| WO-2024006796-A2 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023229993-A1 | OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA | CURATIVE BIOTECHNOLOGY, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| EP-4277703-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | Children's Hospital Medical Center (US) | 2023-11-22 | — | — | EP | claimed |
| US-11814623-B2 | Methods of treating a wound using epigenetic regulation | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-14 | — | — | US | claimed |
| US-20230084515-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING BRAF AND/OR MEK INHIBITOR COMBINATION THERAPY | DUET BIOSYSTEMS, INC. | 2023-03-16 | — | — | US | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| US-20230047313-A1 | TREATING HEART DISEASE IN MUSCULAR DYSTROPHY PATIENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-16 | — | — | US | claimed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | claimed |
| US-20220331389-A1 | SKIN COMPOSITION | EADERM CO., LTD. (JP) | 2022-10-20 | — | — | US | claimed |
| WO-2022155495-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-21 | — | — | WO | claimed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | claimed |
| US-11298372-B2 | Composition for ameliorating loss of hair and graying of hair, and use thereof | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2022-04-12 | — | — | US | claimed |
| EP-3978020-A1 | SKIN COMPOSITION | National University Corporation Tokyo Medical and Dental University (JP) | 2022-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | NOX4, NOX1, NOX3 | CYBB 4/4885NOX5 6/4885NOX4 1/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | CYBB 6/4885NOX5 4/4885NOX4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.